← Back to Search

Repetitive Transcranial Magnetic Stimulation

rTMS for Schizophrenia

N/A
Recruiting
Led By Xiaoming Du, PhD
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights

Study Summary

This trial will study how rTMS affects patients with SSD, measuring biomarkers before and after to assess the effects.

Who is the study for?
This trial is for men and women aged 18-65 with schizophrenia-spectrum disorder who can consent to participate. Excluded are those with major medical conditions affecting the brain, high clozapine doses, failed TMS screening, significant head injury or surgery, pregnancy without contraception, metal implants near the head, seizure history, or recent substance abuse.Check my eligibility
What is being tested?
The study tests active versus sham (fake) repetitive transcranial magnetic stimulation (rTMS) on patients with schizophrenia. It aims to see how rTMS affects certain biomarkers related to the disorder by comparing results before and after treatment in separate sessions.See study design
What are the potential side effects?
While not explicitly listed here, common side effects of rTMS may include headaches or discomfort at the stimulation site. More serious but rare risks involve seizures or hearing loss if proper ear protection isn't used during treatment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change of mismatch negativity (MMN) from electroencephalography (EEG) signals by active and sham rTMS
Change of resting-state functional connectivity (rsFC) by active and sham rTMS

Trial Design

2Treatment groups
Experimental Treatment
Group I: Sham rTMS first and active rTMS secondExperimental Treatment1 Intervention
Participants in this arm will receive sham rTMS in one visit first, then receive active rTMS in another visit.
Group II: Active rTMS first and sham rTMS secondExperimental Treatment1 Intervention
Participants in this arm will receive active rTMS in one visit first, then receive sham rTMS in another visit.

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
688 Previous Clinical Trials
374,596 Total Patients Enrolled
66 Trials studying Schizophrenia
10,197 Patients Enrolled for Schizophrenia
Xiaoming Du, PhDPrincipal InvestigatorUniversity of Maryland, Baltimore
2 Previous Clinical Trials
170 Total Patients Enrolled
2 Trials studying Schizophrenia
170 Patients Enrolled for Schizophrenia

Media Library

rTMS (Repetitive Transcranial Magnetic Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT05660018 — N/A
Schizophrenia Research Study Groups: Sham rTMS first and active rTMS second, Active rTMS first and sham rTMS second
Schizophrenia Clinical Trial 2023: rTMS Highlights & Side Effects. Trial Name: NCT05660018 — N/A
rTMS (Repetitive Transcranial Magnetic Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05660018 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the magnitude of participants currently involved in this research project?

"Affirmative. Clinicaltrials.gov states that this clinical trial is currently searching for participants, with the initial posting on January 7th 2023 and the most recent update occurring in March 30th of the same year. In total, 60 patients are being enrolled from a single site."

Answered by AI

Does this trial offer access to participants who are younger than 55 years old?

"This research is open to those aged 18 or above, up until 65 years old."

Answered by AI

Might I be eligible to participate in this research endeavor?

"To meet the eligibility requirements for this medical trial, individuals must be diagnosed with schizophrenia and between 18-65 years old. A total of 60 patients are needed to take part in this study."

Answered by AI

Are any vacancies still available for the clinical trial?

"Affirmative. According to information housed on clinicaltrials.gov, this medical trial is currently recruiting participants; the initial post was made on July 1st 2023 and underwent its most recent update in March of 30th 2023. The research team aims to recruit 60 patients from a single site."

Answered by AI

Who else is applying?

What state do they live in?
New Jersey
What site did they apply to?
University of Maryland, Baltimore
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
2
Recent research and studies
clinicaltrials.govStudy
TMS Related Biomarker Assessments
Xiaoming Du 2023. "TMS Related Biomarker Assessments". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05660018.
~40 spots leftby Dec 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top